Linagliptin Zentiva

Linagliptin, the active ingredient in Linagliptin Zentiva, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves blood glucose control when used with diet and exercise. - Combination therapy: enhances glycaemic control when added to metformin or other antidiabetic agents. - Adjunct to lifestyle modification: supports maintenance of target HbA1c levels in adult patients.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as cough or sore throat. - Headache: transient and usually mild. - Nasopharyngitis: inflammation of the nasal passages and throat. - Diarrhoea: occasional loose stools. - Nausea: occasional feeling of queasiness. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity: angioedema or anaphylactic reactions. - Hepatic dysfunction: elevated liver enzymes indicating possible liver injury. - Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing kidney disease. - Heart failure exacerbation: worsening symptoms in susceptible individuals.

Before initiating Linagliptin, consider patient‑specific factors and monitor appropriately.

- Renal impairment: dose adjustment may be required in severe renal dysfunction. - Hepatic disease: use with caution in patients with liver impairment. - Cardiovascular risk: monitor for signs of heart failure, especially in high‑risk patients. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Linagliptin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin plasma concentrations. - Combination with other DPP‑4 inhibitors: increased risk of adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics and antihypertensives: may enhance risk of dehydration and hypotension. - Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed. - NSAIDs: may affect renal function when used together in susceptible patients.